Monoclonal antibody therapy for pancreas cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/574
A61K-039/395
C07K-016/30
A61K-039/00
출원번호
US-0011631
(2011-01-21)
등록번호
US-9034588
(2015-05-19)
발명자
/ 주소
Arlen, Myron
Tsang, Kwong
출원인 / 주소
Precision Biologics, Inc.
대리인 / 주소
Teskin, Robin L.
인용정보
피인용 횟수 :
2인용 특허 :
14
초록
The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
대표청구항▼
1. A method for detecting whether a subject has a pancreatic carcinoma comprising: (a) removing a specimen from a subject being diagnosed for a pancreatic carcinoma,(b) contacting said specimen with a monoclonal antibody 31.1, fragment or functional equivalent thereof, and(c) detecting the presence
1. A method for detecting whether a subject has a pancreatic carcinoma comprising: (a) removing a specimen from a subject being diagnosed for a pancreatic carcinoma,(b) contacting said specimen with a monoclonal antibody 31.1, fragment or functional equivalent thereof, and(c) detecting the presence of an antigen-antibody complex, wherein the presence of an antigen-antibody complex indicates the presence of pancreatic cancer. 2. The method of claim 1, wherein said antibody is reactive with pancreatic cancer cells. 3. The method of claim 2, wherein said antibody is reactive with malignant cancer cells. 4. The method of claim 1, wherein said antibody is recombinant. 5. The method of claim 1, wherein said antibody is a chimerized, co-specific, or humanized antibody. 6. The method of claim 5, wherein said chimerized antibody is expressed by a cell line deposited under ATCC Accession Number 12316. 7. The method of claim 1, wherein said functional equivalent is selected from the group consisting of a single chain antibody, a F(ab) fragment, and a F(ab)2 fragment. 8. The method of claim 1, wherein said specimen is tissue or cells. 9. The method of claim 1, wherein the specimen is surgically obtained from the subject suspected of having pancreatic cancer. 10. The method of claim 1, wherein the light chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, or a humanized variant of SEQ ID NO: 1 or SEQ ID NO: 3. 11. The method of claim 1, wherein the heavy chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 4, SEQ ID NO: 6, or a humanized variant of SEQ ID NO: 4 or SEQ ID NO: 6. 12. The method of claim 1, wherein said antibody or fragment is conjugated to a bioactive agent. 13. The method of claim 1, wherein said antibody-antigen complex is detected by an assay selected from the group consisting of Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), “sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays. 14. The method of claim 1, wherein said method further comprises physical examination or a radiological study to detect the presence of pancreatic cancer. 15. The method of claim 14, wherein said radiological study is a chest X-ray, computerized tomography, magnetic resonance imaging, or ultrasound. 16. The method of claim 1, wherein said subject has cancer or is at risk for cancer. 17. The method of claim 1, wherein said antibody is affixed to a microtiter plate. 18. An imaging method for detecting a pancreatic carcinoma antigen in a subject comprising (a) contacting pancreatic cells with a labeled monoclonal antibody 31.1, fragment or functional equivalent thereof; and(b) detecting pancreatic cells that specifically binds to said labeled antibody or fragment, wherein said specific binding indicates the presence of pancreatic carcinoma cells that express said antigen. 19. A method for diagnosing pancreatic cancer in a subject comprising (a) removing a pancreatic cell containing specimen from a subject suspected of having a pancreatic carcinoma;(b) contacting the specimen with a monoclonal antibody 31.1, fragment or functional equivalent thereof, wherein the light chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, or a humanized variant of SEQ ID NO: 1 or SEQ ID NO: 3, and wherein the heavy chain of said antibody is encoded by the nucleotide sequence of SEQ ID NO: 4, SEQ ID NO: 6, or a humanized variant of SEQ ID NO: 4 or SEQ ID NO: 6; and(c) detecting the presence of an antigen-antibody complex,wherein the presence of an antigen-antibody complex correlates to the presence of pancreatic cancer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (14)
Baca, Manuel; Wells, James A., Anti-VEGF antibodies.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Oceanside CA) Horwitz Arnold H. (Los Angeles CA) Better Marc (Los Angeles CA) Wall Randolph (Sherman Oaks CA) Lei Shau-Ping (Los Angeles CA) Wilcox Ga, Modular assembly of antibody genes, antibodies prepared thereby and use.
Hellstrm Ingegerd (Seattle WA) Brown Joseph P. (Seattle WA) Hellstrm Karl E. (Seattle WA) Horn Diane (Seattle WA) Linsley Peter (Seattle WA), Monoclonal antibodies for human non-small cell lung carinomas.
Sakamoto Junichi (New York NY) Cordon-Cardo Carlos (New York NY) Friedman Eileen (New York NY) Finstad Connie L. (New York NY) Enker Warren E. (Englewood NJ) Melamed Myron R. (Scarsdale NY) Lloyd Ken, Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies.
Bander Neil H. (New York NY) Whitmore Willet F. (New York NY) Old Lloyd J. (New York NY), Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.